Vanguard (BLFS) Amendment shows 0 shares and 0% after Jan 12, 2026 realignment
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0%, for BioLife Solutions Inc. The filing states an internal realignment on January 12, 2026 resulted in disaggregated reporting by subsidiaries; the amendment is signed on March 26, 2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
The filing lists an amount beneficially owned of 0 and Percent of class of 0%. It attributes the reporting change to an internal realignment on January 12, 2026 and disaggregation of subsidiary holdings.
Cash‑flow treatment and any prior holdings are not stated in the excerpt; subsequent filings or registrants may show redistributed positions by specific Vanguard subsidiaries.
Amendment explains reliance on SEC Release No. 34-39538 for disaggregated reporting.
The text cites SEC Release No. 34-39538 (January 12, 1998) as the basis for separate reporting by Vanguard subsidiaries. The filing clarifies that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" over securities held by those units.
Investors should note this is a reporting/attribution change; the excerpt does not state transactions or changes in aggregate shareholder ownership levels.
FAQ
What does Vanguard report in the Schedule 13G/A for BLFS?
Does the filing indicate Vanguard sold BLFS shares?
When did Vanguard's internal realignment occur for the BLFS filing?
Who signed the Schedule 13G/A amendment for BLFS?
Does the filing show any Vanguard subsidiary holdings in BLFS?